EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study

Angela Zanfardino iD, Dario Iafusco, Giorgia Ippolito, Emanuele Miraglia Del Giudice, Assunta Serena Rollato, Antonietta Chianese, Adele Figuccia, Sonia Toni, Annalisa Giulia Ferlito, Barbara Piccini

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71101 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Angela Zanfardino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre for Pediatric Diabetes, Department of Pediatrics, University of the Study of Campania, Naples, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Insulin Infusion Systems, Hypoglycemic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Automated insulin delivery (AID) systems improve glycaemic outcomes in Type 1 diabetes; however, paediatric real‐world data on newly introduced tubeless AID systems remain limited. We aimed to provide the first clinical evaluation of the A8 TouchCare Nano AID system with the APGO algorithm in children and adolescents with Type 1 diabetes. Materials and Methods In this prospective observational study, children and adolescents initiating TouchCare Nano AID therapy were followed for 6 months. Continuous glucose monitoring metrics were assessed at baseline and 1, 3 and 6 months. The primary outcome was change in time in range (TIR, 70–180 mg/dL). Secondary outcomes included time in tight range (TiTR, 70–140 mg/dL), time above and below range, glucose variability, insulin dose, achievement of ISPAD glycaemic targets and safety. HbA1c was measured at baseline, 3 and 6 months.

Results

Seventy‐six participants (mean age 13.3 ± 3.2 years) completed follow‐up. Mean TIR increased from 59.0% ± 15.6% at baseline to 74.2% ± 8.9% at 1 month and remained significantly higher at 3 and 6 months (all p < 0.05). TiTR significantly improved, whilst time above range decreased and time below range remained stable. More than half of participants achieved the ISPAD target of TIR > 70% at 6 months. Mean sensor glucose and glucose variability declined, and HbA1c decreased from 7.4% ± 0.8% to 6.9% ± 0.7% at 3 and 6 months (all p < 0.05). No episodes of severe hypoglycaemia or diabetic ketoacidosis were observed.

Conclusions

In routine paediatric care, use of this tubeless AID system was associated with rapid and sustained improvements in glycaemic control without increased hypoglycaemia. Trial Registration: Clinicaltrials.gov : NCT07425912.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1InsulinInsulin Infusion SystemsHypoglycemic AgentsHumansAdolescentFemaleMaleChildContinuous Glucose MonitoringProspective StudiesBlood GlucoseGlycated HemoglobinHypoglycemiaGlycemic ControlTreatment OutcomeAdaptive AlgorithmsAlgorithmsBlood Glucose Self-Monitoring

Stichwörter der Autor:innen

A8 TouchCare Nano systemartificial pancreasautomated insulin delivery (AID)diabetes technologyhybrid closed‐loopinsulin pump

Substanzen

InsulinHypoglycemic AgentsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Regional Centre for Pediatric Diabetes, Department of Pediatrics, University of the Study of Campania, Naples, Italy.
  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy.
  • Diabetology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.

ORCID-Profile: Angela Zanfardino

Zitieren

APA

Zanfardino, A., Iafusco, D., Ippolito, G., Del Giudice, E. M., Rollato, A. S., Chianese, A., Figuccia, A., Toni, S., Ferlito, A. G., & Piccini, B. (2026). Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71101

Vancouver

Zanfardino A, Iafusco D, Ippolito G, Del Giudice EM, Rollato AS, Chianese A, et al. Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71101

BibTeX
@article{Zanfardino2026,
  author = {Zanfardino, Angela and Iafusco, Dario and Ippolito, Giorgia and Del Giudice, Emanuele Miraglia and Rollato, Assunta Serena and Chianese, Antonietta and Figuccia, Adele and Toni, Sonia and Ferlito, Annalisa Giulia and Piccini, Barbara},
  title = {Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71101}
}
Kostenlos starten →